Haematologica (Nov 2017)

Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases

  • Staci D. Arnold,
  • Ruta Brazauskas,
  • Naya He,
  • Yimei Li,
  • Richard Aplenc,
  • Zhezhen Jin,
  • Matt Hall,
  • Yoshiko Atsuta,
  • Jignesh Dalal,
  • Theresa Hahn,
  • Nandita Khera,
  • Carmem Bonfim,
  • Navneet S. Majhail,
  • Miguel Angel Diaz,
  • Cesar O. Freytes,
  • William A. Wood,
  • Bipin N. Savani,
  • Rammurti T. Kamble,
  • Susan Parsons,
  • Ibrahim Ahmed,
  • Keith Sullivan,
  • Sara Beattie,
  • Christopher Dandoy,
  • Reinhold Munker,
  • Susana Marino,
  • Menachem Bitan,
  • Hisham Abdel-Azim,
  • Mahmoud Aljurf,
  • Richard F. Olsson,
  • Sarita Joshi,
  • Dave Buchbinder,
  • Michael J. Eckrich,
  • Shahrukh Hashmi,
  • Hillard Lazarus,
  • David I. Marks,
  • Amir Steinberg,
  • Ayman Saad,
  • Usama Gergis,
  • Lakshmanan Krishnamurti,
  • Allistair Abraham,
  • Hemalatha G. Rangarajan,
  • Mark Walters,
  • Joseph Lipscomb,
  • Wael Saber,
  • Prakash Satwani

DOI
https://doi.org/10.3324/haematol.2017.169581
Journal volume & issue
Vol. 102, no. 11

Abstract

Read online

Advances in allogeneic hematopoietic cell transplantation for sickle cell disease have improved outcomes, but there is limited analysis of healthcare utilization in this setting. We hypothesized that, compared to late transplantation, early transplantation (at age